Bizoran 5/40

Indications

Bizoran is indicated for the management of hypertension, either as a standalone therapy or in conjunction with other antihypertensive medications. It is particularly useful for patients who may require multiple antihypertensive agents to reach their blood pressure targets. The decision to use this combination therapy should be individualized based on factors such as baseline blood pressure, target goals, and the comparative efficacy of combination therapy versus monotherapy. Blood pressure goals can vary according to individual patient risk profiles.

Pharmacology

Bizoran combines Amlodipine, a dihydropyridine calcium channel blocker, and Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB). Amlodipine works by inhibiting calcium ion influx into vascular smooth muscle, leading to reduced peripheral resistance and lower blood pressure. It enhances coronary blood flow by decreasing afterload. Olmesartan Medoxomil blocks the effects of angiotensin II, a potent vasoconstrictor, by selectively binding to AT1 receptors in various tissues, thus reducing vasoconstriction and aldosterone secretion.

Dosage & Administration

Start with a daily dose of 5/20 mg for 1 to 2 weeks, adjusting as needed up to 10/40 mg once daily. Elderly patients, particularly those over 75 years, should start with 2.5 mg of Amlodipine. Initial therapy with this combination is not recommended for patients over 75 years old.

Consult your healthcare provider for personalized dosing recommendations.

Interaction

The antihypertensive effect of Olmesartan Medoxomil may be reduced by NSAIDs, including selective COX-2 inhibitors. Monitoring of blood pressure, renal function, and electrolytes is advised when using this combination with other RAS-affecting agents.

Contraindications

This medication should not be used with Aliskiren in diabetic patients.

Side Effects

Common side effects include peripheral edema, headache, flushing, and dizziness. It may also cause sprue-like enteropathy, a type of intestinal disorder.

Pregnancy & Lactation

Pregnancy Category D. This combination should not be used during the 2nd and 3rd trimesters due to risks of fetal death. If pregnancy occurs, discontinue the medication immediately. The safety of this combination during breastfeeding is not well-established, so a decision should be made whether to continue breastfeeding or discontinue the drug.

Precautions & Warnings

Caution is required in patients who are volume- or salt-depleted, those with severe aortic stenosis, and those with severe obstructive coronary artery disease, as it may worsen angina or acute myocardial infarction.

Use in Special Populations

• Pediatric Use: Safety and efficacy have not been established in children.
• Geriatric Use: No significant differences in safety or effectiveness compared to younger patients.
• Renal Impairment: No specific studies available.
• Hepatic Impairment: Not recommended for initial therapy in patients with liver impairment.

Overdose Effects

Information on overdose is limited. Symptomatic treatment and supportive measures are recommended.

Therapeutic Class

Combined antihypertensive preparations

Storage Conditions

Store below 30°C, away from light, and out of reach of children.